This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Upcoming Deadline: The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Chelsea Therapeutics International Ltd. Of Class Action Lawsuit And The Deadline Of June 4, 2012 To Seek A Lead Plaintiff Position

NEW YORK, May 21, 2012 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of North Carolina on behalf of investors who purchased Chelsea Therapeutics International Ltd. (" Chelsea" or the "Company") (Nasdaq: CHTP) stock between November 3, 2008 and March 28, 2012.

(Logo: )

For more information, click here:  There is no cost or obligation to you.

The complaint alleges that Chelsea made a series of materially false and misleading statements regarding the safety and efficacy of the drug Northera and the likelihood of its approval by the U.S. Food and Drug Administration ("FDA").  On February 13, 2012, Chelsea disclosed that the FDA had raised questions regarding the size and duration of its clinical trials for Northera.  Furthermore, the FDA indicated that three deaths were potentially related to the drug.  As a result of the aforementioned, shares of Chelsea stock declined more than 37 percent.  Then on March 28, 2012, the Company announced that their New Drug Application for Northera was rejected by the FDA.  Upon this news, Chelsea shares fell more than 28 percent, to close at $2.62 per share on March 29, 2012.

If you suffered a loss in Chelsea you have until June 4, 2012 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at or by telephone at (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq.30 Broad Street - 24th Floor New York, NY 10004            Tel: (212) 363-7500Toll Free:  (877) 363-5972Fax: (212) 363-7171

SOURCE Levi & Korsinsky

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,797.52 -0.97 -0.01%
S&P 500 2,085.67 -4.44 -0.21%
NASDAQ 5,117.0420 -10.4830 -0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs